Propionic Acid

Propionic Acid

SCHEMBL4157652

CCC(=O)O.O=c1[nH]c2ccc(S(=O)(=O)NC3CCCCC3)cc2c2cc[nH]c12

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.56
PARG Q86W56 1/20 0.53
BRAF P15056 1/20 0.48
ALDH1A1 P00352 5/20 0.46
TAS2R14 Q9NYV8 1/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 5/20 0.42
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
MGAT2 Q10469 1/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL4153174 1.00 TDP1 (0.56) TDP1PARGBRAFALDH1A1TAS2R14
Propionic Acid SCHEMBL4153577 0.96 PARG (0.57) TDP1PARGBRAFALDH1A1TAS2R14
Propionic Acid SCHEMBL4168582 0.93 PARG (0.51) TDP1PARGBRAFALDH1A1TAS2R14
SCHEMBL4713589 0.92 TDP1 (0.61) TDP1PARGBRAFALDH1A1TAS2R14
Butyric Acid SCHEMBL4161248 0.90 PARG (0.55) TDP1PARGBRAFALDH1A1KMT2A
Propionic Acid SCHEMBL4163336 0.89 PARG (0.47) TDP1PARGBRAFALDH1A1TAS2R14
Butyric Acid SCHEMBL4164937 0.87 PARG (0.49) TDP1PARGBRAFALDH1A1TAS2R14
Propionic Acid SCHEMBL4160991 0.85 BRD4 (0.39) TDP1PARGALDH1A1KMT2AMEN1
Valeric Acid SCHEMBL4165049 0.85 PARG (0.47) TDP1PARGBRAFALDH1A1KMT2A
Propionic Acid SCHEMBL4160658 0.85 TAS2R14 (0.49) PARGBRAFALDH1A1TAS2R14PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TDP1 1098/4885PARG 3507/4885BRAF 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.